Compugen (CGEN) SVP exercises options and sells 7,875 Ordinary Shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Compugen Ltd senior vice president of business development Zurit Levine reported a series of option exercises and share sales. On April 7–8, 2026, Levine exercised share options for a total of 7,875 Ordinary Shares at exercise prices of $0.8292 and $1.15, then sold 7,875 Ordinary Shares in open-market transactions at prices of $2.30 and $2.42. Following these transactions, Levine directly holds 29,375 Ordinary Shares. The filing notes these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025.

Insider Trade Summary 10b5-1

Net Seller: 7,875 shares ($18,758)

Net Sell 8 txns

Insider Levine Zurit

Role SVP, Business Development

Sold 7,875 shs ($19K)

Type	Security	Shares	Price	Value
Exercise	Share Option (right to buy)	4,375	$0.00	--
Exercise	Share Option (right to buy)	1,000	$0.00	--
Exercise	Ordinary Shares	4,375	$0.8292	$4K
Exercise	Ordinary Shares	1,000	$1.15	$1K
Sale	Ordinary Shares	5,375	$2.42	$13K
Exercise	Share Option (right to buy)	2,500	$0.00	--
Exercise	Ordinary Shares	2,500	$0.8292	$2K
Sale	Ordinary Shares	2,500	$2.30	$6K

Holdings After Transaction: Share Option (right to buy) — 6,750 shares (Direct); Ordinary Shares — 33,750 shares (Direct)

Footnotes (1)

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

Key Figures

Shares sold: 7,875 shares Sale prices: $2.30 and $2.42 per share Options exercised: 7,875 options +5 more

8 metrics

Shares sold 7,875 shares Total Ordinary Shares sold in open-market transactions

Sale prices $2.30 and $2.42 per share Prices for 2,500 and 5,375 Ordinary Shares sold

Options exercised 7,875 options Total options exercised into Ordinary Shares

Exercise prices $0.8292 and $1.15 per share Strike prices on exercised share options

Post-transaction holdings 29,375 Ordinary Shares Direct holdings after final reported sale

Rule 10b5-1 plan adoption date December 23, 2025 Plan governing the reported transactions

Option expiration November 9, 2032 Expiration date for one exercised option grant

Option expiration August 3, 2033 Expiration date for another exercised option grant

Key Terms

Rule 10b5-1 trading plan, Share Option (right to buy), Ordinary Shares, Exercise or conversion of derivative security, +2 more

6 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Ordinary Shares financial

"underlying_security_title: Ordinary Shares received upon option exercise and later sold."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Exercise or conversion of derivative security regulatory

"transaction_code_description: Exercise or conversion of derivative security for Form 4 code M."

Sale in open market or private transaction regulatory

"transaction_code_description: Sale in open market or private transaction for Form 4 code S."

SVP, Business Development other

"officer_title: SVP, Business Development for reporting person Levine Zurit."

Form 4 Insider Transactions: What Each Field Means →

04/09/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levine Zurit

(Last)

(First)

(Middle)

C/O COMPUGEN LTD.

26 HAROKMIM STREET

(Street)

HOLON

5885849

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
COMPUGEN LTD [ CGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Business Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	04/07/2026		M⁽¹⁾		2,500	A	$0.8292	31,875	D
Ordinary Shares	04/07/2026		S⁽¹⁾		2,500	D	$2.3	29,375	D
Ordinary Shares	04/08/2026		M⁽¹⁾		4,375	A	$0.8292	33,750	D
Ordinary Shares	04/08/2026		M⁽¹⁾		1,000	A	$1.15	34,750	D
Ordinary Shares	04/08/2026		S⁽¹⁾		5,375	D	$2.42	29,375	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option (right to buy)	$0.8292	04/07/2026		M⁽¹⁾			2,500	⁽²⁾	11/09/2032	Ordinary Shares	2,500	$0	11,125	D
Share Option (right to buy)	$0.8292	04/08/2026		M⁽¹⁾			4,375	⁽²⁾	11/09/2032	Ordinary Shares	4,375	$0	6,750	D
Share Option (right to buy)	$1.15	04/08/2026		M⁽¹⁾			1,000	⁽³⁾	08/03/2033	Ordinary Shares	1,000	$0	58,000	D

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025.

2. This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

3. This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

	/s/ Zurit Levine	04/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Compugen (CGEN) executive Zurit Levine report in this Form 4?

Zurit Levine reported exercising share options for 7,875 Ordinary Shares and selling 7,875 Ordinary Shares in open-market trades. These transactions converted options into shares, then into cash, while leaving direct Ordinary Share holdings at 29,375 after the reported activity.

How many Compugen (CGEN) shares did Zurit Levine sell and at what prices?

Levine sold 7,875 Ordinary Shares in total, including 2,500 shares at $2.30 and 5,375 shares at $2.42 per share. These open-market sales followed option exercises and were executed over two days, according to the Form 4 data.

What options did Zurit Levine exercise in the latest Compugen (CGEN) filing?

Levine exercised options covering 7,875 Ordinary Shares. The exercised options included 6,875 shares at an exercise price of $0.8292 and 1,000 shares at $1.15 per share, converting derivative positions into Ordinary Shares before the subsequent sales.

How many Compugen (CGEN) shares does Zurit Levine hold after these transactions?

After the reported exercises and sales, Levine directly holds 29,375 Ordinary Shares. This post-transaction balance comes from the Form 4’s "total shares following transaction" field for the final reported open-market sale on April 8, 2026.

Were Zurit Levine’s Compugen (CGEN) trades made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025. Such pre-arranged plans schedule trades in advance, reducing the significance of the exact timing of the reported sales.

What role does Zurit Levine hold at Compugen (CGEN) according to the Form 4?

The Form 4 identifies Zurit Levine as an officer of Compugen, serving as SVP, Business Development. This officer status means Levine’s equity transactions in Compugen securities must be reported under Section 16 insider reporting rules.